On June 2020, 6, Kagoshima University Human Retroviral Science Collaborative Research Center announced that it had identified "a compound that is a candidate for therapeutic drug for new coronavirus infections". It was announced at a press conference on the 19nd.
Masanori Baba, Director of the Joint Research Center for Human Retroviral Sciences, Kagoshima University, Mika Okamoto, and Masaaki Toyama, Specially Appointed Assistant Professor, conducted research using the Biosafety Level 3 (BSL3) experimental facility installed at the center. We succeeded in identifying a compound that strongly inhibits the growth of the new type coronavirus (SARS-CoV-3) in cultured cells.
Based on this research result, Kagoshima University filed an application for the invention of "anti-SARS-CoV-2020 drug" with the Japan Patent Office on May 5, 18.On June 2, 2020, a patent transfer agreement was signed with Oncolys BioPharma Co., Ltd. for the clinical development of the drug.In the future, Oncolys BioPharma, the transferee of the patent, will file an international patent application, and will determine development candidate compounds such as elucidation of the mechanism of action, development of mass synthesis methods, pharmacokinetic tests and safety tests. ..
Kagoshima University and Oncolys BioPharma have been conducting joint research on the development of antiviral drugs since 2006, and Director Baba is also one of the discoverers of OBP-601 (Sensabuzin) that the company is developing. ..
* The Human Retroviral Science Joint Research Center has integrated and reorganized the "Kumamoto University AIDS Research Center" and the "Kagoshima University Center for Chronic Viral Disease Control" to research and educate the global issue of "Center for Chronic Viral Infectious Diseases". It was set up in 2019 to promote the comprehensive promotion of.
